Current Report Filing (8-k)
November 16 2022 - 5:01PM
Edgar (US Regulatory)
0001349929
false
0001349929
2022-11-16
2022-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 16, 2022
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
Delaware |
|
001-35817 |
|
04-3462475 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-8126
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
VYNT |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
November 16, 2022, Vyant Bio, Inc. (the “Company”) issued a press release announcing that on November 16, 2022, the Company
received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company’s shares of common stock
had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company’s common stock had
regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as
set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed. A copy of the Company’s press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
VYANT
BIO, INC. |
|
|
|
|
Date: |
November
16, 2022 |
By: |
/s/
John A. Roberts |
|
|
Name: |
John
A. Roberts |
|
|
Title: |
President
and Chief Executive Officer |
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From May 2024 to Jun 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2023 to Jun 2024